
    
      Patients will receive 3 induction cycles of bortezomib, lenalidomide and dexamethasone (VRD)
      followed by high dose melphalan and autologous stem cell transplantation. Two months after
      haematological recovery, patients will receive 2 consolidation cycles of VRD and maintenance
      therapy for 1 year with lenalidomide
    
  